AI assistant
IRADIMED CORP — Director's Dealing 2024
Dec 13, 2024
32324_dirs_2024-12-13_492a6800-f0f9-4bf2-ba46-bd4396f43724.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: IRADIMED CORP (IRMD)
CIK: 0001325618
Period of Report: 2024-12-11
Reporting Person: GLENN JOHN (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-12-11 | Restricted Stock Units | $ | A | 5436 | Acquired | Common Stock (5436) | Direct | |
| 2024-12-11 | Performance-based Restricted Stock Units | $ | A | 5435 | Acquired | Common Stock (5435) | Direct |
Footnotes
F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2: The reporting person received RSUs under Iradimed Corporation's 2023 Equity Incentive Plan. The RSUs vest in three equal annual installments beginning on December 11, 2025. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.
F3: The reporting person received performance-based restricted stock units ("PRSUs") under Iradimed Corporation's 2023 Equity Incentive Plan. PRSUs convert into common stock on a one-for-one basis. The PRSUs vest over a three-year performance period from December 12, 2024 through December 11, 2027 on the Company's total stockholder return compared to the NASDAQ US Small Cap Medical Equipment index.